Format

Send to

Choose Destination
Clin Cancer Res. 2015 Feb 15;21(4):934. doi: 10.1158/1078-0432.CCR-14-2832.

Ang1 and Tie2 are predictive biomarkers for bevacizumab-letter.

Author information

1
Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Laboratoire de Pharmacocinétique Clinique, Marseille, France. Aix Marseille University, Simulation and Modelling, Adaptive Response for Therapeutics in Cancer (SMARTc), Inserm U911 CRO2, Marseille, France. joseph.ciccolini@univ-amu.fr.
2
Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Laboratoire de Pharmacocinétique Clinique, Marseille, France. Aix Marseille University, Simulation and Modelling, Adaptive Response for Therapeutics in Cancer (SMARTc), Inserm U911 CRO2, Marseille, France.
3
Aix Marseille University, Simulation and Modelling, Adaptive Response for Therapeutics in Cancer (SMARTc), Inserm U911 CRO2, Marseille, France.
4
Aix Marseille University, Simulation and Modelling, Adaptive Response for Therapeutics in Cancer (SMARTc), Inserm U911 CRO2, Marseille, France. Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Multidisciplinary Oncology and Therapeutic Innovations Department, Marseille, France.
PMID:
25691775
DOI:
10.1158/1078-0432.CCR-14-2832
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center